AbbreviationTerminology
AAAfrican-American
AASKAASK, African-American Study of Kidney Disease and Hypertension Trial
ACCORDAction to Control Cardiovascular Risk in Diabetes trial
ACEAngiotensin-converting enzyme
ACE-IAngiotensin-converting enzyme inhibitors
ADAAmerican Diabetes Association
AEsAdverse events/effects
AFCAPS/TexCAPSAir Force/Texas Coronary Atherosclerosis Prevention Study
AGIAlpha-glucosidase inhibitor
AIIRAAngiotensin II receptor antagonists
ALLHATAntihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
ALLHAT-LLAAntihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial-Lipid Lowering Arm
ALTAlanine aminotransferase
AMIAcute myocardial infarction
ARBsAngiotensin II receptor blocker
ARRAbsolute risk reduction
ASCOT-LLAAnglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm
ASTAspartate aminotransferase
AUCArea under the curve
BGBlood glucose
bidTwo times daily
BIPBezafibrate Infarction Prevention Trial
BMIBody mass index
BPBlood pressure
BPLTTCBlood Pressure Lowering Treatment Trialists' Collaboration
CControl group
CABGCoronary artery bypass graft
CARDSCollaborative AtoRvastatin Diabetes Study
CDControlled diet
CDCCenter for Disease Control and Prevention
CDEConventional dietary education
CECost effectiveness
CHDCoronary heart disease
CHFCongestive heart failure
COERControlled-onset extended-release
CONVINCEControlled ONset Verapamil Investigation of Cardiovascular Endpoints Trial
CORECenter for Outcomes REsearch
CVDCardiovascular disease
DBPDiastolic blood pressure
DBTTarget blood pressure
DCCTDiabetes Control and Complications Trial
DMDiabetes
DM1Type 1 diabetes mellitus
DM2Type 2 diabetes mellitus
DPPDiabetes Prevention Program
DPSFinnish Diabetes Prevention Study
DREAMDiabetes Reduction Assessment with Ramipril and Rosiglitazone Medication
DSC-Type 2Diabetes Symptom Checklist - Type 2
EFEjection fraction
EKG (or ECG)Electrocardiogram
ESRDEnd-stage renal disease
FBGFasting blood glucose
Fin-D2DNational Type 2 Diabetes Prevention Program in Finland
FPGFasting plasma glucose
GIGlucose intolerance
GPDMGeneral practitioner group with diabetes
HADSHospital Anxiety and Depression Scale
HAIHealth Anxiety Inventory
HCTZHydrochlorothiazide;
HDLHigh density lipoprotein
HMOHealth maintenance organization
HOPEHeart Outcomes Prevention Evaluation study
HOTHypertension Optimal Treatment
HPSHeart Protection Study
HRHazard ratio
HRQoLHealth Related Quality of Life questionnaire
HTHypertension
HxHistory
IIntervention group
IDNTIrbesartan Diabetic Nephropathy Trial
IGTImpaired glucose tolerance
IFGImpaired fasting glucose
ITTIntention to treat analysis
JMIC-BJapan Multi-center Investigation for Cardiovascular Diseases-B
LDLLow density lipoprotein
LELife expectancy
LEALower extremity amputation
LFTLiver function test
LIFELosartan Intervention for Endpoint Reduction Trial
LIPIDLong-term Intervention with Pravastatin in Ischaemic Disease
LSMLifestyle Modification
LTPALeisure time physical activity
LVEFLeft ventricular ejection fraction
LVHLeft ventricular hypertrophy
LYLife year
mMonths
MCSMental Component Score
MIMyocardial infarction
NANot applicable
NCEPNational Cholesterol Education Project
NDENew dietary education
NFGNormal fasting glucose
NGNormoglycemic
NGTNondiabetic or normal glucose tolerance
NHANESNational Health and Nutrition Examination Survey
NICOLENisoldipine In Coronary Artery Disease in Leuven
nonDMWithout diabetes
NNTNumber needed to treat
NRNot reported
NSDNot significant
NSDNo significant difference
NYHANew York Heart Association
OGTTOral glucose tolerance test
OPOutpatient
OROdds ratio
PAPhysical activity
PAIDProblem Areas in Diabetes scale
PART2Prevention of Atherosclerosis with Ramipril Therapy
PCSPhysical Component Score
preDMPrediabetes
PPGPostprandial plasma glucose
PPPPrimary Prevention Project trial
PREVENTProspective Randomized Evaluation of the Vascular Effects of Norvasc Trial
PROGRESSPerindopril Protection Against Recurrent Stroke Study
PROSPERProspective Study of Pravastatin in the Elderly at Risk trial
QALEQuality-adjusted life expectancy
QALYQuality-adjusted life year
qEvery
qdDaily
QOLQuality of life
RCTRandomized controlled trial
RDRisk difference
RENAALRandomized Evaluation of Non-Insulin-Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan
RFReduced fat
RRRelative risk
RRRRelative risk reduction
RTIResearch Triangle International
SBPSystolic blood pressure
SCOPEStudy on Cognition and Prognosis in the Elderly
SDStandard deviation
SDMScreened group with diabetes
SF-12Medical Outcomes Study Short Form 12
SF-36Medical Outcomes Study Short Form 36
SRQSymptom Risk Questionnaire
SSAI-SFSpielburger State-Trait Anxiety Scale-Short Form
STOP-NIDDMStudy TO Prevent Non-Insulin-Dependent Diabetes Mellitus
SYST-EURSystolic Hypertension-Europe trial
TCTotal cholesterol
TGTriglycerides
TIATransient ischemic attack
tidThree times daily
TZDsThiazolidinediones
UAPUnstable angina pectoris
UKPDSUnited Kingdom Prospective Diabetes Study
ULNUpper limit of normal
WWhite
WBQ-12Well-being Questionnaire 12
WHIWomen's Health Initiative
WHOWorld Health Organization
wksWeeks
WOSCOSWest of Scotland Coronary Prevention Study
XENDOSXenical in the Prevention of Diabetes in Obese Subjects
yYear

From: Appendix A Definitions and Abbreviations

Cover of Screening for Type 2 Diabetes Mellitus: Update of 2003 Systematic Evidence Review for the U.S. Preventive Services Task Force
Screening for Type 2 Diabetes Mellitus: Update of 2003 Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].
Evidence Syntheses, No. 61.
Norris SL, Kansagara D, Bougatsos C, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.